Discovering potential therapeutics that can modulate the tissue-specific expression/activation of adiponectin and its receptors AdipoR1/AdipoR2 can pave the way to treat tissue-specific effects of MetS. This evidence concerns the gene ADIPOR2 and metabolic syndrome.